Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.

van Staa TP, Card T, Logan RF, Leufkens HG.

Gut. 2005 Nov;54(11):1573-8. Epub 2005 Jun 30. Review.

2.

[Inflammatory bowel disease and colorectal cancer].

Hagymási K, Tulassay Z.

Orv Hetil. 2006 Oct 15;147(41):1977-82. Review. Hungarian.

PMID:
17120688
4.

Drug insight: aminosalicylates for the treatment of IBD.

Nielsen OH, Munck LK.

Nat Clin Pract Gastroenterol Hepatol. 2007 Mar;4(3):160-70. Review.

PMID:
17339853
5.

[Colorectal cancer in inflammatory bowel disease].

Henriksen M, Moum B.

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2696-9. Review. Norwegian.

6.

The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.

Herfarth H.

Dig Dis. 2012;30 Suppl 2:55-9. doi: 10.1159/000341894. Epub 2012 Nov 23. Review.

PMID:
23207933
7.

Chemoprevention for colon cancer: new opportunities, fact or fiction?

Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ.

Scand J Gastroenterol Suppl. 2006;(243):158-64. Review.

PMID:
16782636
8.

Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.

Munkholm P.

Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5. Review.

PMID:
12950413
9.

Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.

Chan EP, Lichtenstein GR.

Gastroenterol Clin North Am. 2006 Sep;35(3):675-712. Review.

PMID:
16952746
10.
11.

The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).

Klotz U.

Arzneimittelforschung. 2012 Feb;62(2):53-8. doi: 10.1055/s-0031-1299685. Epub 2012 Feb 16. Review.

PMID:
22344548
12.

Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.

Munkholm P, Loftus EV Jr, Reinacher-Schick A, Kornbluth A, Mittmann U, Esendal B.

Digestion. 2006;73(1):11-9. Epub 2006 Jan 10. Review.

PMID:
16410688
13.

Systematic review: the use of mesalazine in inflammatory bowel disease.

Bergman R, Parkes M.

Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55. Review.

14.

Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.

Schroeder KW.

Scand J Gastroenterol Suppl. 2002;(236):42-7. Review.

PMID:
12408503
15.

Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.

Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH.

Inflamm Bowel Dis. 2002 Sep;8(5):356-61. Review.

PMID:
12479651
16.

Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.

Ryan BM, Russel MG, Langholz E, Stockbrugger RW.

Am J Gastroenterol. 2003 Aug;98(8):1682-7. Review.

PMID:
12907319
17.

[Association between membranous glomerulonephritis and Crohn's disease].

Díaz Rodríguez C, Granja E, Vázquez Martul E, Sacristán F, Moreno Fernández A, González Rivero C, del Río Romero D, Trinidad JC.

Nefrologia. 2004;24(4):368-71. Review. Spanish.

18.

Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Dyson JK, Rutter MD.

World J Gastroenterol. 2012 Aug 7;18(29):3839-48. doi: 10.3748/wjg.v18.i29.3839. Review.

19.

5-Aminosalicylic acid and chemoprevention: does it work?

Lopez A, Peyrin-Biroulet L.

Dig Dis. 2013;31(2):248-53. doi: 10.1159/000353806. Epub 2013 Sep 6. Review.

PMID:
24030235
20.

Inflammatory bowel disease.

Gibson PR, Iser J.

Aust Fam Physician. 2005 Apr;34(4):233-7. Review.

PMID:
15861742

Supplemental Content

Support Center